[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553433":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":25,"responsibleParty":36,"collaborators":25,"id":38,"slug":25,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":25,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":25,"studyType":50,"phases":51,"briefSummary":54,"conditions":55,"keywords":25,"overallStatus":57,"whyStopped":25,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":25},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Magnesium Sulphate 1g\u002Fhr","ACTIVE_COMPARATOR","Women in this group will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 1 g\u002Fh.",[13],"Drug: maintenance magnesium sulphate1g\u002Fh",{"label":15,"type":10,"description":16,"interventionNames":17},"Magnesium Sulphate 2g\u002Fhr","Women in this group will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 2 g\u002Fh.",[18],"Drug: maintenance magnesium sulphate2g\u002Fh",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","maintenance magnesium sulphate1g\u002Fh","Women will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 1 g\u002Fh.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"maintenance magnesium sulphate2g\u002Fh","Women will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 2 g\u002Fh.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Rehab Hashem","CONTACT","01017830916","rehabhashem66@gmail.com",{"type":37,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100553433",false,"NCT06486025","Protocols for Magnesium Sulfate Maintenance Dose in Overweight and Obese Women Diagnosed With Preeclampsia","ALTERNATE DOSING PROTOCOL FOR MAGNESIUM SULFATE IN OVERWEIGHT AND OBESE WOMEN WITH PREECLAMPISA: A RANDOMIZED CONTROLLED TRIAL","Inclusion Criteria:\n\nWomen diagnosed with SPET as per criteria of NICE, 2023 guidance\n\n* Age 20-40 years\n* BMI \\>25kg\u002Fm2\n* Gestational age \\> 28 weeks\n\nExclusion Criteria:\n\n* Intrauterine Fetal Death (IUFD)\n* Hemolysis - Elevated liver enzymes - Low platelets syndrome (HELLP)\n* Contraindication to Magnesium Sulfate such as myasthenia gravis, severe renal failure, cardiac ischemia, and heart block\n* Serum creatinine levels greater than 1.1 mg\u002FdL.\n* Women refusing to participate in the study.","FEMALE","20 Years","40 Years",{"count":48,"type":49},100,"ESTIMATED","INTERVENTIONAL",[52,53],"PHASE1","PHASE2","There is still no evidence of the appropriate dose to be used. Serum magnesium sulfate concentration is not measured regularly, thus we may be using sub-therapeutic level or reaching a toxic level.Overweight and obese women have different pharmacokinetics and different drug distribution, therefore, they may need higher doses of magnesium sulfate to reach therapeutic level.",[56],"Severe Preeclampsia","NOT_YET_RECRUITING","2024-06-27",{"date":60,"type":61},"2024-07-03","ACTUAL",{"date":63,"type":49},"2024-07-01",{"date":65,"type":49},"2024-10-01",{"name":5,"class":6}]